Latest Healthcare Research Reports

Tag: biologics contract development market forecast

  • Biologics Contract Development Market Developments Influencing Industry Expansion Through 2030

    Biologics Contract Development Market Developments Influencing Industry Expansion Through 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Market Size Is Forecasted For The Biologics Contract Development Market By 2030 Based On Its 2026 Value?

    The biologics contract development market size has experienced rapid growth in recent years. It is projected to expand from $8.55 billion in 2025 to $9.53 billion in 2026, at a compound annual growth rate (CAGR) of 11.4%. This historic growth can be attributed to several factors, including the increasing complexity of biologics pipelines, rising costs associated with in-house manufacturing, the expansion of monoclonal antibody development, the growth of early-stage biologics research, and an increasing reliance on specialized CDMOs.

    The biologics contract development market size is poised for substantial expansion over the next few years. It is forecast to reach $14.46 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.0%. This anticipated growth during the forecast period stems from factors such as increasing demand for rapid biologics scale-up, rising investments in advanced mammalian cell platforms, the expansion of oncology biologics pipelines, a growing emphasis on flexible manufacturing capacity, and the increasing adoption of digital bioprocess optimization. Prominent trends throughout this period include an increasing outsourcing of biologics process development, rising demand for scalable cell line development, the growing adoption of single-use bioprocessing systems, the expansion of integrated cdmo service models, and an enhanced focus on speed-to-clinic development.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp

    What Influential Factors Are Boosting The Biologics Contract Development Market Demand?

    The increasing incidence of chronic diseases is anticipated to drive the biologics contract development market forward. Chronic diseases are defined as conditions lasting a year or more that necessitate continuous medical attention. The growing number of chronic disease cases escalates the demand for developing new drugs, including biologics, thereby fostering the biologics contract development market. For example, in September 2024, data released by the Office for Health Improvement & Disparities, a UK-based government body, revealed that in the first half of 2023, there were 3,940 excess deaths attributed to chronic lower respiratory diseases, marking a 30% rise compared to expected levels. By the end of the year, this count increased to 5,363, indicating a 22% overall increase. Therefore, the expanding prevalence of chronic diseases will stimulate the growth of the biologics contract development market.

    How Is Segment Classification Applied In The Biologics Contract Development Market?

    The biologics contract development market covered in this report is segmented –

    1) By Source: Microbial, Mammalian, Other Sources

    2) By Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Indications

    3) By Product Service: Cell Line Development, Process Development, Other Product Services

    Subsegments:

    1) By Microbial: Bacterial Sources, Yeast Sources, Fungal Sources

    2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Hybridoma Cells

    3) By Other Sources: Plant-Based Systems, Insect Cell Systems, Algal Sources

    What Trends Are Driving Changes In The Biologics Contract Development Market?

    Leading companies in biologics contract development are focusing on embedding data analytics into their processes. These major firms are integrating digital technologies and data analytics into biologics development procedures to improve process monitoring, data analysis, and decision-making, thereby enhancing both efficiency and productivity. For instance, in October 2023, WuXi Biologics, a China-based biologics contract development and manufacturing entity, unveiled its WuXiUI high-productivity bioprocessing platform. WuXiUI represents WuXi Biologics’ proprietary ultra-intensified intermittent-perfusion fed-batch platform, which has been successfully developed and applied both internally and in client-facing biologics development and manufacturing endeavors. It facilitates capabilities such as real-time monitoring of critical process parameters via integrated Process Analytical Technology tools, optimization of cell culture productivity, and prediction of product quality and yield profiles under varying process conditions, given suitable process data inputs.

    Who Are The Firms Contributing To The Biologics Contract Development Market Ecosystem?

    Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Syngene International Limited, Vibalogics GmbH, Yposkesi

    Access The Complete Biologics Contract Development Market Report:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    Which Region Leads The Biologics Contract Development Market By Size?

    North America was the largest region in the biologics contract development market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Biologics Contract Development Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=8219&type=smp

    Browse Through More Reports Similar to the Global Biologics Contract Development Market 2026, By The Business Research Company

    Biologics Outsourcing Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

    Biologics Testing Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

    Biopharmaceuticals Contract Manufacturing Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Increasing coronary artery disease cases are driving expansion in the coronary artery disease market

    Increasing coronary artery disease cases are driving expansion in the coronary artery disease market

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    “What Is The Forecasted Market Size Trajectory Of The Coronary Artery Disease Market From 2026 To 2030?

    The coronary artery disease market has experienced rapid growth in recent years. Its value is projected to rise from $31.88 billion in 2025 to $35.27 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. The expansion observed in the past can be attributed to elements such as the widespread occurrence of cardiovascular disease, sedentary lifestyles, tobacco consumption, insufficient understanding of preventive care, and healthcare models centered around hospitals.

    The coronary artery disease market is anticipated to experience substantial growth in the upcoming years, projected to reach $53.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.2%. This expansion during the forecast period is primarily driven by factors such as the aging global population, increasing obesity rates, advancements in diagnostic technologies, the growth of preventive cardiology, and improved healthcare access. Significant trends expected during this period include a heightened focus on early disease detection, the rising application of combination drug therapies, the development of lifestyle modification programs, an expansion of minimally invasive treatments, and the integration of cardiac rehabilitation services.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report

    Which Major Drivers Are Influencing The Expansion Of The Coronary Artery Disease Market?

    The increasing incidence of coronary artery disease is projected to drive the expansion of the coronary artery disease market over the forthcoming years. Coronary artery disease (CAD) refers to a medical condition characterized by the constricting or blocking of the coronary arteries, which are responsible for supplying blood to the heart muscle. Cases of coronary artery disease are escalating due to evolving dietary patterns, heightened stress levels, inadequate exercise, obesity, aging, and other contributing factors. Coronary artery disease is managed with pharmaceuticals such as clopidogrel, ticagrelor, warfarin, and heparin, and through procedures like coronary artery bypass grafting, angioplasty, and stenting. For example, in October 2025, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2023, an estimated 2,700 acute coronary events occurred among First Nations people aged 25 and older. When accounting for the population’s age structure, the frequency of these events was 2.8 times higher than what was observed in non-Indigenous people. Therefore, the rise in the prevalence of coronary artery disease is anticipated to boost the coronary artery disease market during the forecast period.

    What Are The Key Segment Divisions In The Coronary Artery Disease Market Segment Structure?

    The coronary artery disease market covered in this report is segmented –

    1) By Treatment: Medication, Surgery, Additional Therapy, Other Treatments

    2) By Diagnosis: Electrocardiogram, Echocardiogram, Stress Test, Cardiac Catheterization, Heart CT Scan, Other Diagnosis

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

    4) By End-User: Hospitals, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Medication: Antiplatelet Agents, Beta-Blockers, Statins, ACE Inhibitors

    2) By Surgery: Coronary Artery Bypass Grafting, Angioplasty And Stenting, Heart Valve Surgery

    3) By Additional Therapy: Cardiac Rehabilitation, Lifestyle Modification Programs, Alternative Therapies

    4) By Other Treatments: Gene Therapy, Stem Cell Therapy, Innovative Devices

    Which Trends Are Shaping The Coronary Artery Disease Market?

    Leading firms in the coronary artery disease market are concentrating on creating novel products, like drug-coated balloon catheters, to boost their earnings within the market. These drug-coated balloon catheters represent medical devices utilized in interventional cardiology to address constricted or obstructed blood vessels, specifically for coronary artery disease or peripheral artery disease. As an example, in March 2024, Boston Scientific Corporation, a US-based medical device manufacturer, revealed that the US Food and Drug Administration (FDA) had approved its AGENT Drug-Coated Balloon (DCB), designed for treating coronary in-stent restenosis (ISR) in individuals with coronary artery disease. ISR refers to the blockage or tightening of a stented blood vessel due to plaque or scar tissue formation. The AGENT DCB presents a specialized treatment alternative for the difficult issue of in-stent restenosis (ISR), thereby fulfilling a crucial unmet medical requirement. Its design specifically targets the treatment of ISR and also addresses previously unmanaged small vessel coronary disease. Currently accessible in Europe, certain regions of Asia Pacific, and Latin America, the AGENT DCB delivers a focused remedy for these intricate cardiovascular ailments.

    Which Organizations Are Engaged In The Coronary Artery Disease Market?

    Major companies operating in the coronary artery disease market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Wockhardt Ltd., Kowa Pharmaceuticals America Inc., Barr Pharmaceuticals Inc., AdvanceCor GmbH, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) e.V.

    Get The Full Coronary Artery Disease Market Report:

    https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report

    Which Region Is The Leading Market For The Coronary Artery Disease Market?

    North America was the largest region in the coronary artery disease market in 2025. The regions covered in the coronary artery disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Coronary Artery Disease Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report

    Browse Through More Reports Similar to the Global Coronary Artery Disease Market 2026, By The Business Research Company

    Coronary Pressure Market Report 2026

    https://www.thebusinessresearchcompany.com/report/coronary-pressure-global-market-report

    Acute Coronary Syndrome Market Report 2026

    https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

    Coronary Stents Market Report 2026

    https://www.thebusinessresearchcompany.com/report/coronary-stents-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model”

  • Biologics Contract Development Market to Reach $14.46B by 2030 at 11% CAGR

    Biologics Contract Development Market to Reach $14.46B by 2030 at 11% CAGR

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Projected Increase In Market Value Of The Biologics Contract Development Market During 2026–2030?

    The biologics contract development market size has seen substantial growth in recent years. This market is expected to expand from $8.55 billion in 2025 to $9.53 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.4%. The increase observed in the past can be attributed to increasing biologics pipeline complexity, rising costs of in-house manufacturing, expansion of monoclonal antibody development, growth of early-stage biologics research, and increasing reliance on specialized cdmos.

    The biologics contract development market is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $14.46 billion, exhibiting a compound annual growth rate (CAGR) of 11.0%. This anticipated growth throughout the forecast period stems from factors such as a heightened need for accelerated biologics scale-up, augmented investments in sophisticated mammalian cell platforms, an expanding array of oncology biologics pipelines, a heightened emphasis on adaptable manufacturing capabilities, and the wider incorporation of digital bioprocess optimization. Key developments expected during this period involve a greater propensity for outsourcing biologics process development, an escalating requirement for scalable cell line development, broader implementation of single-use bioprocessing systems, the proliferation of integrated CDMO service paradigms, and a stronger concentration on accelerating development to clinic.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    Which Factors Are Influencing The Growth Of The Biologics Contract Development Market?

    The increasing incidence of long-term illnesses is projected to boost the biologics contract development market in the future. Chronic diseases are defined as conditions persisting for a year or more, necessitating continuous medical care. This growth in chronic disease instances fuels the need for new drug development, particularly biologics, consequently fostering the biologics contract development market. An illustrative example comes from September 2024, where reports from the UK’s Office for Health Improvement & Disparities indicated 3,940 excess deaths from chronic lower respiratory diseases in the first half of 2023, a 30% increase over anticipated figures. The annual total reached 5,363, an overall rise of 22%. Consequently, the growing occurrence of chronic diseases is set to stimulate expansion within the biologics contract development market.

    What Are The Key Segment Divisions In The Biologics Contract Development Market Segment Structure?

    The biologics contract development market covered in this report is segmented –

    1) By Source: Microbial, Mammalian, Other Sources

    2) By Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Indications

    3) By Product Service: Cell Line Development, Process Development, Other Product Services

    Subsegments:

    1) By Microbial: Bacterial Sources, Yeast Sources, Fungal Sources

    2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Hybridoma Cells

    3) By Other Sources: Plant-Based Systems, Insect Cell Systems, Algal Sources

    Which Trends Are Influencing Demand In The Biologics Contract Development Market?

    Major companies involved in biologics contract development are concentrating on incorporating data analytics into their operational frameworks. These companies are integrating digital technologies and advanced data analytics into biologics development to improve process oversight, data interpretation, and strategic decision-making, ultimately enhancing efficiency and productivity. For instance, in October 2023, WuXi Biologics, a China-based company specializing in biologics contract development and manufacturing, launched its WuXiUI high-productivity bioprocessing platform. This WuXiUI platform represents WuXi Biologics’ proprietary ultra-intensified intermittent-perfusion fed-batch system, which has been successfully implemented for internal use and in client-focused biologics development and manufacturing projects. It facilitates, among other functions, real-time tracking of crucial process parameters using integrated Process Analytical Technology tools, optimizing cell culture productivity, and predicting product quality and yield profiles under varying process conditions, provided suitable process data inputs are available.

    Which Organizations Are Engaged In The Biologics Contract Development Market?

    Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Syngene International Limited, Vibalogics GmbH, Yposkesi

    Get The Full Biologics Contract Development Market Report:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    Where Is The Biologics Contract Development Market Primarily Concentrated By Region?

    North America was the largest region in the biologics contract development market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Biologics Contract Development Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    Browse Through More Reports Similar to the Global Biologics Contract Development Market 2026, By The Business Research Company

    Biopharmaceuticals Contract Manufacturing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Biologics Outsourcing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

    Biologics Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biologics Contract Development Market to Reach $14.46B by 2030 at 11% CAGR

    Biologics Contract Development Market to Reach $14.46B by 2030 at 11% CAGR

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Projected Increase In Market Value Of The Biologics Contract Development Market During 2026–2030?

    The biologics contract development market size has seen substantial growth in recent years. This market is expected to expand from $8.55 billion in 2025 to $9.53 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.4%. The increase observed in the past can be attributed to increasing biologics pipeline complexity, rising costs of in-house manufacturing, expansion of monoclonal antibody development, growth of early-stage biologics research, and increasing reliance on specialized cdmos.

    The biologics contract development market is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $14.46 billion, exhibiting a compound annual growth rate (CAGR) of 11.0%. This anticipated growth throughout the forecast period stems from factors such as a heightened need for accelerated biologics scale-up, augmented investments in sophisticated mammalian cell platforms, an expanding array of oncology biologics pipelines, a heightened emphasis on adaptable manufacturing capabilities, and the wider incorporation of digital bioprocess optimization. Key developments expected during this period involve a greater propensity for outsourcing biologics process development, an escalating requirement for scalable cell line development, broader implementation of single-use bioprocessing systems, the proliferation of integrated CDMO service paradigms, and a stronger concentration on accelerating development to clinic.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    Which Factors Are Influencing The Growth Of The Biologics Contract Development Market?

    The increasing incidence of long-term illnesses is projected to boost the biologics contract development market in the future. Chronic diseases are defined as conditions persisting for a year or more, necessitating continuous medical care. This growth in chronic disease instances fuels the need for new drug development, particularly biologics, consequently fostering the biologics contract development market. An illustrative example comes from September 2024, where reports from the UK’s Office for Health Improvement & Disparities indicated 3,940 excess deaths from chronic lower respiratory diseases in the first half of 2023, a 30% increase over anticipated figures. The annual total reached 5,363, an overall rise of 22%. Consequently, the growing occurrence of chronic diseases is set to stimulate expansion within the biologics contract development market.

    What Are The Key Segment Divisions In The Biologics Contract Development Market Segment Structure?

    The biologics contract development market covered in this report is segmented –

    1) By Source: Microbial, Mammalian, Other Sources

    2) By Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Indications

    3) By Product Service: Cell Line Development, Process Development, Other Product Services

    Subsegments:

    1) By Microbial: Bacterial Sources, Yeast Sources, Fungal Sources

    2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Hybridoma Cells

    3) By Other Sources: Plant-Based Systems, Insect Cell Systems, Algal Sources

    Which Trends Are Influencing Demand In The Biologics Contract Development Market?

    Major companies involved in biologics contract development are concentrating on incorporating data analytics into their operational frameworks. These companies are integrating digital technologies and advanced data analytics into biologics development to improve process oversight, data interpretation, and strategic decision-making, ultimately enhancing efficiency and productivity. For instance, in October 2023, WuXi Biologics, a China-based company specializing in biologics contract development and manufacturing, launched its WuXiUI high-productivity bioprocessing platform. This WuXiUI platform represents WuXi Biologics’ proprietary ultra-intensified intermittent-perfusion fed-batch system, which has been successfully implemented for internal use and in client-focused biologics development and manufacturing projects. It facilitates, among other functions, real-time tracking of crucial process parameters using integrated Process Analytical Technology tools, optimizing cell culture productivity, and predicting product quality and yield profiles under varying process conditions, provided suitable process data inputs are available.

    Which Organizations Are Engaged In The Biologics Contract Development Market?

    Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Syngene International Limited, Vibalogics GmbH, Yposkesi

    Get The Full Biologics Contract Development Market Report:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    Where Is The Biologics Contract Development Market Primarily Concentrated By Region?

    North America was the largest region in the biologics contract development market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Biologics Contract Development Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    Browse Through More Reports Similar to the Global Biologics Contract Development Market 2026, By The Business Research Company

    Biopharmaceuticals Contract Manufacturing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Biologics Outsourcing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

    Biologics Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • One of the Major Drivers of the Biologics Contract Development Market Is the Surge In Chronic Diseases Drives Demand, Fueling Growth In The Biologics Contract Development Market

    One of the Major Drivers of the Biologics Contract Development Market Is the Surge In Chronic Diseases Drives Demand, Fueling Growth In The Biologics Contract Development Market

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Value Is Expected For The Biologics Contract Development Market At The End Of The 2026–2030 Forecast Period?

    The biologics contract development market has experienced rapid expansion in recent years. Its value is forecast to increase from $8.55 billion in 2025 to $9.53 billion in 2026, with a compound annual growth rate (CAGR) of 11.4%. The growth observed in the historic period can be attributed to the increasing biologics pipeline complexity, rising costs of in-house manufacturing, expansion of monoclonal antibody development, growth of early-stage biologics research, and an increasing reliance on specialized cdmos.

    The biologics contract development market size is anticipated to experience substantial growth in the upcoming years. It is forecast to expand to $14.46 billion in 2030, achieving a compound annual growth rate (CAGR) of 11.0%. This projected expansion during the forecast period stems from factors such as increasing demand for rapid biologics scale-up, greater investments in advanced mammalian cell platforms, the broadening of oncology biologics pipelines, a heightened focus on flexible manufacturing capacity, and the rising adoption of digital bioprocess optimization. Significant trends expected in this period include increased outsourcing of biologics process development, growing demand for scalable cell line development, wider integration of single-use bioprocessing systems, the expansion of integrated CDMO service models, and an intensified emphasis on accelerating speed-to-clinic development.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp

    Which Market Drivers Are Supporting The Expansion Of The Biologics Contract Development Market?

    The increasing occurrence of chronic illnesses is anticipated to propel the biologics contract development market into the future. Chronic diseases are defined as conditions persisting for a year or more, necessitating continuous medical care. An uptick in chronic illness instances escalates the need for creating new medications, such as biologics, consequently fostering the biologics contract development market. As an illustration, reports released by the Office for Health Improvement & Disparities, a UK-based government, in September 2024, indicated that during the first half of 2023, 3,940 excess deaths were linked to chronic lower respiratory diseases, representing a 30% rise over anticipated figures. Over the full year, this figure climbed to 5,363, demonstrating a 22% overall surge. Consequently, the growing frequency of chronic diseases is set to fuel the expansion of the biologics contract development market.

    What Segment Types Make Up The Biologics Contract Development Market?

    The biologics contract development market covered in this report is segmented –

    1) By Source: Microbial, Mammalian, Other Sources

    2) By Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Indications

    3) By Product Service: Cell Line Development, Process Development, Other Product Services

    Subsegments:

    1) By Microbial: Bacterial Sources, Yeast Sources, Fungal Sources

    2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Hybridoma Cells

    3) By Other Sources: Plant-Based Systems, Insect Cell Systems, Algal Sources

    What Industry Trends Are Redefining The Biologics Contract Development Market?

    Major companies engaged in biologics contract development are increasingly concentrating on embedding data analytics into their development processes. These firms are integrating digital technologies and data analytics within biologics development to improve process monitoring, data analysis, and informed decision-making, which consequently enhances efficiency and productivity. A notable example occurred in October 2023, when WuXi Biologics, a China-based biologics contract development and manufacturing company, introduced its WuXiUI high-productivity bioprocessing platform. WuXiUI represents WuXi Biologics’ proprietary ultra-intensified intermittent-perfusion fed-batch platform, which has been successfully developed and applied both internally and in biologics development and manufacturing projects for clients. This platform notably enables real-time observation of critical process parameters via integrated Process Analytical Technology tools, optimizes cell culture productivity, and predicts product quality and yield profiles under various process conditions, contingent on suitable process data inputs.

    Who Are The Key Players Driving Competition In The Biologics Contract Development Market?

    Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Syngene International Limited, Vibalogics GmbH, Yposkesi

    Read the full biologics contract development market report here:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    How Is The Biologics Contract Development Market Distributed Across Key Geographic Regions?

    North America was the largest region in the biologics contract development market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Biologics Contract Development Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=8219&type=smp

    Browse Through More Reports Similar to the Global Biologics Contract Development Market 2026, By The Business Research Company

    Biologics Outsourcing Global Market Report

    https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

    Biologics Testing Global Market Report

    https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

    Biopharmaceuticals Contract Manufacturing Global Market Report

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biologics Contract Development Market Future Outlook 2026: Key Drivers and Growth Potential

    Biologics Contract Development Market Future Outlook 2026: Key Drivers and Growth Potential

    Uncover key drivers, emerging technologies, and competitive movements shaping the biologics contract development market from 2026–2035 with trusted insights from The Business Research Company

    What is the expected shift in the Biologics Contract Development Market’s size between 2026 and 2030?

    The biologics contract development market size has experienced rapid expansion in recent years. It is projected to grow from $8.55 billion in 2025 to $9.53 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.4%. The market’s historical growth can be attributed to the increasing complexity of biologics pipelines, rising costs associated with in-house manufacturing, the expansion of monoclonal antibody development, the growth of early-stage biologics research, and an increasing reliance on specialized cdmos.

    The biologics contract development market size is anticipated to experience substantial expansion over the next few years. It is predicted to attain a value of $14.46 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.0%. This market growth throughout the forecast period is propelled by factors such as the increasing demand for rapid biologics scale-up, growing investments in advanced mammalian cell platforms, the broadening of oncology biologics pipelines, an intensifying focus on flexible manufacturing capacity, and the rising adoption of digital bioprocess optimization. Noteworthy trends projected for this period encompass the increasing outsourcing of biologics process development, heightened demand for scalable cell line development, wider embrace of single-use bioprocessing systems, the expansion of integrated CDMO service models, and an intensified drive towards speed-to-clinic development.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp

    Which Drivers Are Shaping Strategic Decisions In The Biologics Contract Development Market?

    The increasing occurrence of chronic diseases is anticipated to advance the biologics contract development market. Chronic diseases are defined as conditions persisting for a year or more that necessitate continuous medical care. The growth in chronic disease cases fuels the need for new drug development, including biologics, thus boosting the biologics contract development market. For example, in September 2024, reports released by the Office for Health Improvement & Disparities, a UK-based government entity, indicated that the first half of 2023 saw 3,940 excess deaths due to chronic lower respiratory diseases, a 30% rise from anticipated figures. Over the entire year, this figure climbed to 5,363, showing a 22% overall increase. Consequently, the expanding prevalence of chronic diseases will propel the expansion of the biologics contract development market.

    What Segment Categories Are Covered In The Biologics Contract Development Market?

    The biologics contract development market covered in this report is segmented –

    1) By Source: Microbial, Mammalian, Other Sources

    2) By Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Indications

    3) By Product Service: Cell Line Development, Process Development, Other Product Services

    Subsegments:

    1) By Microbial: Bacterial Sources, Yeast Sources, Fungal Sources

    2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Hybridoma Cells

    3) By Other Sources: Plant-Based Systems, Insect Cell Systems, Algal Sources

    What Upcoming Trends Are Likely To Define The Future Path Of The Biologics Contract Development Market?

    Leading companies engaged in biologics contract development are increasingly incorporating data analytics into their processes. These organizations are integrating digital technologies and data analytics within biologics development workflows to enhance process monitoring, data analysis, and decision-making, thereby improving efficiency and productivity. For example, in October 2023, WuXi Biologics, a China-based biologics contract development and manufacturing company, introduced its WuXiUI high-productivity bioprocessing platform. WuXiUI is WuXi Biologics’ proprietary ultra-intensified intermittent-perfusion fed-batch platform, which has been successfully developed and implemented both internally and for client-facing biologics development and manufacturing projects. It facilitates, among other things, real-time monitoring of critical process parameters through integrated Process Analytical Technology tools, optimizes cell culture productivity, and predicts product quality and yield profiles under various process conditions, given suitable process data inputs.

    Which Major Industry Participants Are Leading The Biologics Contract Development Market Growth?

    Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Syngene International Limited, Vibalogics GmbH, Yposkesi

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    Which Region Is Expected To Experience The Fastest Growth In The Biologics Contract Development Market?

    North America was the largest region in the biologics contract development market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Biologics Contract Development Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=8219&type=smp

    Browse Through More Reports Similar to the Global Biologics Contract Development Market 2026, By The Business Research Company

    Biopharmaceuticals Contract Manufacturing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Biologics Outsourcing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

    Biologics Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Biologics Contract Development Market 2025–2029: Unveiling Growth Developments with the Latest Updates

    Global Biologics Contract Development Market 2025–2029: Unveiling Growth Developments with the Latest Updates

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    How Much Will The Biologics Contract Development Market Be Worth By 2029?

    The size of the biologics contract development market has seen rapid expansion in the past few years. Rising from $7.75 billion in 2024, it is estimated to extend to $8.55 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%. Factors contributing to growth during the historic period include the expansion of the biologics market, the increase in biopharmaceuticals, the intricacy of biologics, patent expirations, and cost efficiency.

    The market size of biologics contract development is slated for a significant surge in the forthcoming years, with an estimated worth of $13.08 billion by 2029, expanding at a compound annual growth rate (CAGR) of 11.2%. This anticipated expansion during the forecast period is due in large part to elements such as data analytics and digitalization, risk management strategies, enhanced flexibility and scalability, a substantial increase in R&D investments, and advancements in precision medicine and personalized treatments. Major forecast period trends exploring regenerative medicine, risk management initiatives, global partnerships, advanced technology deployments and technology integration will also contribute to this growth.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp

    What Market Forces Are Contributing To The Growth Of The Biologics Contract Development Market?

    The escalating incidence of sustained illnesses is projected to drive the growth of the biologics contract development market. Sustained illnesses refer to health issues persisting for over a year, necessitating continuous medical care. The increasing number of long-term disease cases prompts the need for new drug creation, including biologics, thus fostering the biologics contract development market. For example, the Office for Health Improvement & Disparities in the UK reported in September 2024 that there were 3,940 deaths in excess due to chronic lower respiratory diseases in just the first half of 2023, signifying a 30% surge in comparison to projected rates. For the full year, this figure climbed to 5,363, representing an overall 22% increase. Consequently, the escalating instances of sustained diseases will fuel the expansion of the biologics contract development market.

    Which Segments Define The Structure Of The Biologics Contract Development Market?

    The biologics contract developmentmarket covered in this report is segmented –

    1) By Source: Microbial; Mammalian; Others Sources

    2) By Indication: Oncology; Immunological Disorders; Cardiovascular Disorders; Hematological Disorders; Others Indications

    3) By Product Service: Cell Line Development; Process Development; Others Product Services

    Subsegments:

    1) By Microbial: Bacterial Sources; Yeast Sources; Fungal Sources

    2) By Mammalian: Chinese Hamster Ovary (CHO) Cells; Human Embryonic Kidney (HEK) Cells; Hybridoma Cells

    3) By Other Sources: Plant-Based Systems; Insect Cell Systems; Algal Sources

    Which Long-Term Trends Will Play A Crucial Role In The Biologics Contract Development Market?

    The biologics contract development market is witnessing a rise in the adoption of innovative technologies. To maintain their competitive edge, major firms in this sector are integrating cutting-edge technologies. An example of this is Lonza, a Swiss contract manufacturing and development solutions firm, which introduced the bYlok technology platform in January 2022. This platform facilitates the design and production of bispecific antibodies, resolving the light-heavy chain mispairing problem with more than 95% precision, high yields, and the ability to preserve a mAb-like format. Pharmaceutical and biotechnology companies can easily avail this technology through a straightforward research license.

    Which Firms Are Making The Biggest Impact In The Biologics Contract Development Market?

    Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, STC Biologics, Siegfried Evionnaz SA, BioAgilytix Labs Inc., Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., AbbVie Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Meridian Life Science Inc., Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Sartorius AG, Syngene International Limited, Vibalogics GmbH, Yposkesi

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    Which Region Is Forecasted To Lead The Biologics Contract Development Market In The Coming Years?

    North America was the largest region in the biologics contract development market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=8219&type=smp

    Browse Through More Reports Similar to the Global Biologics Contract Development Market 2025, By The Business Research Company

    Chemicals Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/chemicals-global-market-report

    Ethylene Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/ethylene-global-market-report

    Genetically Modified Crops Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/genetically-modified-crops-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biologics Contract Development Market Trends 2025–2029: Forecasts for Key Growth Segments

    Biologics Contract Development Market Trends 2025–2029: Forecasts for Key Growth Segments

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    By How Much Is The Biologics Contract Development Market Expected To Expand Between 2025 And 2029?

    The biologics contract development market has witnessed rapid expansion in recent years. This market is set to increase from $7.75 billion in 2024 to $8.55 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.3%. Factors contributing to its historical growth include the overall growth of the biologics market, an increase in biopharmaceuticals, the complexity of biologics, patent expirations, and an emphasis on cost efficiency.

    The biologics contract development market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $13.08 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 11.2%. This growth during the forecast period is attributable to elements such as digitalization and data analytics, risk management, flexibility and scalability, increasing investment in r&d, precision medicine, and personalized therapies. Furthermore, significant trends expected in this period include regenerative medicine, risk mitigation strategies, global collaborations, the use of advanced technologies, and comprehensive technological integration.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp

    What Are The Top Growth Drivers Impacting The Biologics Contract Development Market Outlook?

    The increasing prevalence of chronic diseases is projected to drive the biologics contract development market moving forward. Chronic diseases are characterized as illnesses lasting a year or longer, requiring ongoing medical attention. This rise in chronic disease cases elevates the demand for developing new drugs, including biologics, thus boosting the biologics contract development market. For example, reports released in September 2024 by the Office for Health Improvement & Disparities, a UK-based government body, revealed that in the first half of 2023, 3,940 excess deaths were linked to chronic lower respiratory diseases, marking a 30% increase compared to expected rates. For the full year, this figure increased to 5,363, reflecting an overall 22% rise. Hence, the growing occurrence of chronic diseases will propel the growth of the biologics contract development market.

    What Are The Primary Types Of Segments Analyzed In The Biologics Contract Development Market?

    The biologics contract developmentmarket covered in this report is segmented –

    1) By Source: Microbial; Mammalian; Others Sources

    2) By Indication: Oncology; Immunological Disorders; Cardiovascular Disorders; Hematological Disorders; Others Indications

    3) By Product Service: Cell Line Development; Process Development; Others Product Services

    Subsegments:

    1) By Microbial: Bacterial Sources; Yeast Sources; Fungal Sources

    2) By Mammalian: Chinese Hamster Ovary (CHO) Cells; Human Embryonic Kidney (HEK) Cells; Hybridoma Cells

    3) By Other Sources: Plant-Based Systems; Insect Cell Systems; Algal Sources

    Which Key Trends Are Expected To Influence The Biologics Contract Development Market In The Coming Years?

    Technological advancements are becoming increasingly prominent in the biologics contract development market. Major companies within the biologics contract development market are integrating sophisticated technologies to sustain their market position. For example, in January 2022, Lonza, a Switzerland-based contract manufacturing and development solutions company, unveiled its bYlok technology platform specifically for designing and manufacturing bispecific antibodies. This innovation helps to resolve the light-heavy chain mispairing issue, providing high yields, greater than 95% accuracy, and the capacity to maintain a mAb-like format. Pharmaceutical and biotech companies can obtain access to this platform via a simple research license.

    Who Are The Primary Competitors In The Global Biologics Contract Development Market?

    Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, STC Biologics, Siegfried Evionnaz SA, BioAgilytix Labs Inc., Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., AbbVie Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Meridian Life Science Inc., Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Sartorius AG, Syngene International Limited, Vibalogics GmbH, Yposkesi

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    How Does The Biologics Contract Development Market Perform Across Key Geographic Regions?

    North America was the largest region in the biologics contract development market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Biologics Contract Development Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=8219&type=smp

    Browse Through More Reports Similar to the Global Biologics Contract Development Market 2025, By The Business Research Company

    Chemicals Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/chemicals-global-market-report

    Ethylene Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/ethylene-global-market-report

    Genetically Modified Crops Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/genetically-modified-crops-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biologics Contract Development Market Forecast Reaching $13.08 Billion by 2029 at 11.2% CAGR

    Biologics Contract Development Market Forecast Reaching $13.08 Billion by 2029 at 11.2% CAGR

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    #How Has The Biologics Contract Development Market Size Shifted, And What Is the Outlook Through 2034?#_x000D_

    In the last few years, the size of the biologics contract development market has seen a swift increase. The industry is projected to expand from a worth of $7.75 billion in 2024 to $8.55 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.3%. Factors behind the growth during this historic period include an expansion of the biologics market, a surge in biopharmaceuticals, the complexity of biologics, patent expirations, and cost efficiency._x000D_

    _x000D_

    The market size of the biologics contract development is predicted to experience significant expansion in the coming years. Forecasted to attain a value of $13.08 billion by 2029 with a compound annual growth rate (CAGR) of 11.2%, the growth can be credited to factors such as digitalization and data analytics, risk control measures, adaptability, scaling potential, increased investment in research and development, precision medical treatments, and individualized therapies. Key trends during this forecast period include advancements in regenerative medicine, strategic risk management, international partnerships, cutting-edge technologies, and technological unification._x000D_

    _x000D_

    #Download a free sample to assess the report’s scope and structure:#_x000D_

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp_x000D_

    _x000D_

    #Which Major Market Drivers Are Expected to Boost the Growth Potential of the Biologics Contract Development Market?#_x000D_

    The escalating occurrence of long-term illnesses is anticipated to push the growth momentum of the biologics contract development market. Chronic diseases are illnesses with a duration of a year or more, requiring consistent medical care. With the increasing incidents of such diseases, the demand for innovative pharmaceuticals, including biologics, is on the rise. This, in turn, boosts the biologics contract development market. For instance, data from the Office for Health Improvement & Disparities, a UK government body, suggests that the first half of 2023 saw an excess of 3,940 deaths due to chronic lower respiratory diseases. This was a 30% surge when compared with anticipated rates. The number rose to 5,363 for the full year, indicating a 22% overall increase. Thus, the escalating prevalence of chronic diseases is anticipated to fuel the biologics contract development market’s growth._x000D_

    _x000D_

    #Which Key Market Segments Comprise the Biologics Contract Development Market and Drive Its Revenue Growth?#_x000D_

    The biologics contract developmentmarket covered in this report is segmented – _x000D_

    _x000D_

    1) By Source: Microbial; Mammalian; Others Sources_x000D_

    2) By Indication: Oncology; Immunological Disorders; Cardiovascular Disorders; Hematological Disorders; Others Indications_x000D_

    3) By Product Service: Cell Line Development; Process Development; Others Product Services_x000D_

    _x000D_

    Subsegments:_x000D_

    1) By Microbial: Bacterial Sources; Yeast Sources; Fungal Sources _x000D_

    2) By Mammalian: Chinese Hamster Ovary (CHO) Cells; Human Embryonic Kidney (HEK) Cells; Hybridoma Cells _x000D_

    3) By Other Sources: Plant-Based Systems; Insect Cell Systems; Algal Sources _x000D_

    _x000D_

    #Request customized data on this market:#_x000D_

    https://www.thebusinessresearchcompany.com/customise?id=8219&type=smp_x000D_

    _x000D_

    #Which Areas Are Leading Regions in the Biologics Contract Development Market Expansion Across the Globe?#_x000D_

    North America was the largest region in the biologics contract development market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

    _x000D_

    #What Are the Key Market Trends in theBiologics Contract Development Market Over the Coming Years?#_x000D_

    The biologics contract development market is gaining momentum thanks to technological advancements. Prominent players in this sector are adopting novel technologies to maintain their market standing. For example, in January 2022, Lonza, a Swiss firm that provides contract manufacturing and development solutions, introduced the bYlok technology platform. This platform allows for the creation and manufacturing of bispecific antibodies, effectively resolving the light-heavy chain mismatch problem with high output, an accuracy rate exceeding 95%, and the capability to keep a mAb-like format. This technology is easily available to pharmaceutical and biotech companies via a straightforward research license._x000D_

    _x000D_

    #View the full report here:#_x000D_

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report_x000D_

    _x000D_

    #How Is the Biologics Contract Development Market Conceptually Defined?#_x000D_

    Biologics contract development refers to companies that provide biologics development and manufacturing services to pharmaceutical corporations on a contract basis. The biologics contract development is used to outsource the manufacturing of biologics on contracts to focus on the marketing, R&D, and branding of products. _x000D_

    _x000D_

    #Purchase the full report and get a swift delivery:#_x000D_

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8219_x000D_

    _x000D_

    #About The Business Research Company:#_x000D_

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

    _x000D_

    #Get in touch with us:#_x000D_

    The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

    Americas +1 310-496-7795_x000D_

    Europe +44 7882 955267_x000D_

    Asia & Others +44 7882 955267 & +91 8897263534_x000D_

    Email us at info@tbrc.info_x000D_

    _x000D_

    #Follow us on:#_x000D_

    _x000D_

    LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biologics Contract Development Market Forecast Reaching $13.08 Billion by 2029 at 11.2% CAGR

    Biologics Contract Development Market Forecast Reaching $13.08 Billion by 2029 at 11.2% CAGR

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has The Biologics Contract Development Market Size Shifted, And What Is the Outlook Through 2034?

    In the last few years, the size of the biologics contract development market has seen a swift increase. The industry is projected to expand from a worth of $7.75 billion in 2024 to $8.55 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.3%. Factors behind the growth during this historic period include an expansion of the biologics market, a surge in biopharmaceuticals, the complexity of biologics, patent expirations, and cost efficiency.

    The market size of the biologics contract development is predicted to experience significant expansion in the coming years. Forecasted to attain a value of $13.08 billion by 2029 with a compound annual growth rate (CAGR) of 11.2%, the growth can be credited to factors such as digitalization and data analytics, risk control measures, adaptability, scaling potential, increased investment in research and development, precision medical treatments, and individualized therapies. Key trends during this forecast period include advancements in regenerative medicine, strategic risk management, international partnerships, cutting-edge technologies, and technological unification.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp

    Which Major Market Drivers Are Expected to Boost the Growth Potential of the Biologics Contract Development Market?

    The escalating occurrence of long-term illnesses is anticipated to push the growth momentum of the biologics contract development market. Chronic diseases are illnesses with a duration of a year or more, requiring consistent medical care. With the increasing incidents of such diseases, the demand for innovative pharmaceuticals, including biologics, is on the rise. This, in turn, boosts the biologics contract development market. For instance, data from the Office for Health Improvement & Disparities, a UK government body, suggests that the first half of 2023 saw an excess of 3,940 deaths due to chronic lower respiratory diseases. This was a 30% surge when compared with anticipated rates. The number rose to 5,363 for the full year, indicating a 22% overall increase. Thus, the escalating prevalence of chronic diseases is anticipated to fuel the biologics contract development market’s growth.

    Which Key Market Segments Comprise the Biologics Contract Development Market and Drive Its Revenue Growth?

    The biologics contract developmentmarket covered in this report is segmented –

    1) By Source: Microbial; Mammalian; Others Sources

    2) By Indication: Oncology; Immunological Disorders; Cardiovascular Disorders; Hematological Disorders; Others Indications

    3) By Product Service: Cell Line Development; Process Development; Others Product Services

    Subsegments:

    1) By Microbial: Bacterial Sources; Yeast Sources; Fungal Sources

    2) By Mammalian: Chinese Hamster Ovary (CHO) Cells; Human Embryonic Kidney (HEK) Cells; Hybridoma Cells

    3) By Other Sources: Plant-Based Systems; Insect Cell Systems; Algal Sources

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=8219&type=smp

    Which Areas Are Leading Regions in the Biologics Contract Development Market Expansion Across the Globe?

    North America was the largest region in the biologics contract development market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Key Market Trends in theBiologics Contract Development Market Over the Coming Years?

    The biologics contract development market is gaining momentum thanks to technological advancements. Prominent players in this sector are adopting novel technologies to maintain their market standing. For example, in January 2022, Lonza, a Swiss firm that provides contract manufacturing and development solutions, introduced the bYlok technology platform. This platform allows for the creation and manufacturing of bispecific antibodies, effectively resolving the light-heavy chain mismatch problem with high output, an accuracy rate exceeding 95%, and the capability to keep a mAb-like format. This technology is easily available to pharmaceutical and biotech companies via a straightforward research license.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

    How Is the Biologics Contract Development Market Conceptually Defined?

    Biologics contract development refers to companies that provide biologics development and manufacturing services to pharmaceutical corporations on a contract basis. The biologics contract development is used to outsource the manufacturing of biologics on contracts to focus on the marketing, R&D, and branding of products.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8219

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model